Anti-cancer drug mkt gets painfully competitive
The fight in the anti-cancer biotech drug Granulocyte Colony Stimulating Factor (D-CSF) - commonly known as Gratim -segment is getting fierce. Close on the heels of Ranbaxy Laboratories approaching
The fight in the anti-cancer biotech drug Granulocyte Colony Stimulating Factor (D-CSF) - commonly known as Gratim -segment is getting fierce. Close on the heels of Ranbaxy Laboratories approaching